Corrigendum to “Preliminary 3-Year Evaluation of Experience With SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience With 5813 Consecutive Breast Augmentation Cases” Aesthet Surg J. 2018;38(Supplement_2):S62–S73; DOI: https://doi.org/10.1093/asj/sjx150.
After Aesthetic Surgery Journal was alerted to July 13 and 16, 2018 Establishment Labs Holdings, Inc. correspondence with the Securities and Exchange Commission, the author's disclosures have now been amended by the editor, to wit: Dr. Sforza serves as coordinator of the Medical Advisory Board, has a consulting agreement with Establishment Labs Holdings, Inc., is a US clinical trial investigator, has received an option grant in September 2016 for 36,953 Class A Ordinary Shares in Establishment Labs Holdings, Inc., and the author's institution on April 17, 2014 entered into a Supply Agreement with Establishment Labs Holdings, Inc.